Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
52W High
$33.66
52W Low
$2.53
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.17
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
82.68%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
26,014,600
Float
4,505,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2025-03-31 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.16
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.9980
Previous
-1.0108
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025